TSX · EPRX.TO
Eupraxia Pharmaceuticals Inc.
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
Loading market information…
TSXV · NGEN.V · CAD
Stock price, earnings
Quote as of Mar 16, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
NervGen Pharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 39.34% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow NervGen Pharma Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 |
|---|
| Apr 23, 2024 |
| -CA$0.04+57.56% vs estimate |
| CA$0.00 |
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
$10.95+$0.08 (+0.74%)
Fennec Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.36% below the high.
CA$3.67+CA$0.09 (+2.51%)
Auxly Cannabis Group Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.13% below the high.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
CA$8.21+CA$0.12 (+1.48%)
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 33.79% below the high.
CA$14.70+CA$0.03 (+0.2%)
Medical Facilities Corporation’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
CA$9.60+CA$0.57 (+6.31%)
Satellos Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.42% below the high.
CA$4.56+CA$0.00 (0.0%)
HLS Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.72% below the high.
